Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656056 · ClinicalTrials.gov registry record · Phase 1
Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02656056 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 22 participants.
The verdict
NCT02656056, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The consumption of fermented soy foods can alter the human microbiome and may confer health benefits. Researchers propose a line of inquiry to assess the effects of Q-Can Plus ("QC") fermented soy beverage in humans, assessing immunological, microbiological, and clinical parameters.
Interventions
- OTHER Food: (Q-Can Plus fermented soybean beverage)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656056
The ClinicalTrials.gov registry entry for NCT02656056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Food: (Q-Can Plus fermented soybean beverage) is the first listed.
NCT02656056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02656056 about?
NCT02656056 is a clinical study titled "Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome". The consumption of fermented soy foods can alter the human microbiome and may confer health benefits. Researchers propose a line of inquiry to assess the effects of Q-Can Plus ("QC") fermented soy beverage in humans, assessing immunological, microbiological, and clinical parameters.
What is the current status of trial NCT02656056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02656056?
The interventions under investigation include: Food: (Q-Can Plus fermented soybean beverage) (OTHER).
Who is sponsoring clinical trial NCT02656056?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.